As the coronavirus disease 2019 (COVID-19) pandemic has progressed, the recognition of neurologic sequelae has increased. Herein, we report on a case of COVID-19–associated leukoencephalopathy with microhemorrhage.A 59-year-old man with known persistent asthma (managed with inhaled steroids and long-acting beta agonists) presented with upper respiratory symptoms (10 days duration) and fever (7 days duration). COVID-19 was confirmed by means of polymerase chain reaction assay. He was intubated on hospital day 6. Severe agitation required high-dose analgesics (including dilaudid, fentanyl, and morphine), and blood pressure required intermittent pressor support (mean, 70–90 mm Hg, without sustained hypertension). Laboratory results included a platelet count of 175 000/μL, an activated partial thromboplastin clotting time of 34.7 seconds, an international normalized ratio of 1.3, a D-dimer level of 11 720 ng/mL, and a fibrinogen level of 693 mg/dL. Lumbar puncture was not performed.Unenhanced head CT images showed subtle hypoattenuation of the bilateral cerebral hemispheric white matter and corpus callosum (Fig 1). T2-weighted fluid-attenuated inversion recovery MRI scans of the brain revealed diffuse, confluent posterior predominant white matter hyperintensities, scattered microhemorrhages predominantly in the corpus callosum, and apparent posterior circulation hyperperfusion (Fig 2), without diffusion restriction or abnormal enhancement.
Figure 1:
Unenhanced CT image of head demonstrates confluent hypoattenuation in genu (anterior) and splenium (posterior) of corpus callosum (arrows).
Figure 2a:
(a) T2-weighted fluid-attenuated inversion recovery MRI scan of brain shows extensive posterior greater than anterior white matter hyperintensity (arrows) without mass effect. (b) Susceptibility-weighted image demonstrates a cluster of microhemorrhages in corpus callosum (arrows). (c) Arterial-spin-labeling perfusion images are suggestive of posterior circulation hyperperfusion (arrows). CBF = cerebral blood flow.
Unenhanced CT image of head demonstrates confluent hypoattenuation in genu (anterior) and splenium (posterior) of corpus callosum (arrows).(a) T2-weighted fluid-attenuated inversion recovery MRI scan of brain shows extensive posterior greater than anterior white matter hyperintensity (arrows) without mass effect. (b) Susceptibility-weighted image demonstrates a cluster of microhemorrhages in corpus callosum (arrows). (c) Arterial-spin-labeling perfusion images are suggestive of posterior circulation hyperperfusion (arrows). CBF = cerebral blood flow.(a) T2-weighted fluid-attenuated inversion recovery MRI scan of brain shows extensive posterior greater than anterior white matter hyperintensity (arrows) without mass effect. (b) Susceptibility-weighted image demonstrates a cluster of microhemorrhages in corpus callosum (arrows). (c) Arterial-spin-labeling perfusion images are suggestive of posterior circulation hyperperfusion (arrows). CBF = cerebral blood flow.(a) T2-weighted fluid-attenuated inversion recovery MRI scan of brain shows extensive posterior greater than anterior white matter hyperintensity (arrows) without mass effect. (b) Susceptibility-weighted image demonstrates a cluster of microhemorrhages in corpus callosum (arrows). (c) Arterial-spin-labeling perfusion images are suggestive of posterior circulation hyperperfusion (arrows). CBF = cerebral blood flow.These imaging findings are nonspecific and can accompany several well-established leukoencephalopathies. Confluent corpus callosal involvement can occur in acute disseminated encephalomyelitis (1) or acute hemorrhagic encephalomyelitis (2). Microbleeds can be seen with these or other vasculitides (3), as well as with posterior reversible encephalopathy syndrome (note that there was no documented hypertension in this case). Anesthesia-related toxicity is also possible. Although the mechanism of white matter injury and its relationship to COVID-19 is uncertain, possibilities include endotheliitis with thrombotic microangiopathy (4) as well as COVID-19–associated cytokine release syndrome, which may have implications for treatment (5).
Authors: Pedro S Pinto; Ricardo Taipa; Bruno Moreira; Carlos Correia; Manuel Melo-Pires Journal: J Magn Reson Imaging Date: 2011-04 Impact factor: 4.813
Authors: Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch Journal: Lancet Date: 2020-04-21 Impact factor: 79.321
Authors: E Gulko; M L Oleksk; W Gomes; S Ali; H Mehta; P Overby; F Al-Mufti; A Rozenshtein Journal: AJNR Am J Neuroradiol Date: 2020-09-03 Impact factor: 3.825
Authors: M Lang; K Buch; M D Li; W A Mehan; A L Lang; T M Leslie-Mazwi; S P Rincon Journal: AJNR Am J Neuroradiol Date: 2020-06-25 Impact factor: 3.825
Authors: Angelo Ippolito; Hans Urban; Kimia Ghoroghi; Nicolas Rosbach; Neelam Lingwal; Elisabeth H Adam; Benjamin Friedrichson; Andrea U Steinbicker; Elke Hattingen; Katharina J Wenger Journal: Sci Rep Date: 2022-10-19 Impact factor: 4.996
Authors: B C Yoon; K Buch; M Lang; B P Applewhite; M D Li; W A Mehan; T M Leslie-Mazwi; S P Rincon Journal: AJNR Am J Neuroradiol Date: 2020-09-10 Impact factor: 3.825
Authors: O Rapalino; A Weerasekera; S J Moum; K Eikermann-Haerter; B L Edlow; D Fischer; A Torrado-Carvajal; M L Loggia; S S Mukerji; P W Schaefer; R G Gonzalez; M H Lev; E-M Ratai Journal: AJNR Am J Neuroradiol Date: 2020-10-29 Impact factor: 3.825
Authors: S Agarwal; J Conway; V Nguyen; S Dogra; P Krieger; D Zagzag; A Lewis; K Melmed; S Galetta; R Jain Journal: AJNR Am J Neuroradiol Date: 2020-10-22 Impact factor: 3.825